In recent years, metabolic signatures associated with RCC has also stimulated interest in targeted metabolism as a novel therapeutic strategy and in the treatment of RCC, the first metabolic target is mammalian target of rapamycin (mTOR), in addition to promoting HIF1 translation, mTOR complex 1 also drives protein and lipid processing by intercepting signals from glucose, growth factors, and amino acids [5]. Here, MTOR is linked to renal cell carcinoma.